Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Digital Health Trends 2024 - Implications for Research and Patient Care

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI®
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience Solutions with Apple devices
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE

Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions with Apple devices

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.

LEARN MORE
MAIN/Careers
Careers/
IQVIA Careers
Featured Careers
Stay Connected

WE'RE HIRING

"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.

VIEW ROLES
MAIN/Contact Us
Contact Us/
Institute Report
Achieving CAR T-cell Therapy Health System Readiness
An assessment of barriers and opportunities
Mar 20, 2025
To download files you must give consent to process your personal data by clicking the "Accept" button below.

Report Summary:

In this report, the current health system capacity for delivering CAR T-cell therapies to patients was assessed in seven countries (Australia, Canada, France, Germany, Italy, Spain, and the United Kingdom). This includes reimbursement and funding, patient referral, treatment, and long-term follow-up. This report provides background on the complex CAR T-cell therapy patient journey from patient identification and referral to long-term monitoring, and estimates CAR T-cell therapy utilization in a subset of countries.

Key barriers and best practices for enhancing the delivery of CAR T-cell therapies are also highlighted for each country. Based on this assessment and learning from best practices, potential solutions are provided to improve patient access to CAR T-cell therapies. This report is intended to provide a foundation for discussions around key barriers and actions or policies that could be tailored to specific country or regional needs to ensure the full potential of CAR T-cell therapies is realized.

Key Findings:

  • Treatment with CAR T-cell therapy is complex and requires the coordination of a multi-disciplinary team including referring and treating physicians, nurses, and pharmacists, along with other stakeholders that can vary by country, region, or hospital.
  • CAR T-cell therapy share varies across Italy, France, Germany, Spain, and the United Kingdom. The differences in CAR T-cell therapy share uptake among the countries can be driven by several factors, such as the number of treatment centers, the processes for referrals and treatment initiation/administration, and reimbursement dynamics.
  • The analysis of barriers across these dimensions throughout the CAR T journey highlights several issues that can limit optimal delivery in the countries studied in this analysis. These barriers vary across countries. For example, some countries and regions have a well developed referral system, such as France and Australia, while others face substantial challenges at this level, as in Italy and Germany.
  • All countries studied are experiencing issues around capacity and staffing; experts that were interviewed expressed concerns about the workload of current healthcare staff involved with these therapies.
  • The average turnaround times (vein to vein) ranged from 36 days in Spain to 24 days in Canada in Q2 2024. Additionally, the time between referral and commencement of CAR T treatment for DLBCL varies substantially across countries. Across all countries, there were a large proportion of cases that took two months.
  • Some key solutions can be considered to enhance the use of CAR T-cell therapies for eligible and appropriate patients based on identified best practices across countries. These steps will need to be reviewed and adapted for specific national or regional contexts.

Other Findings:

CAR T-cell therapy system and patient journey

  • Treatment with CAR T-cell therapy requires the coordination of a multi-disciplinary team including referring and treating physicians, nurses, pharmacists, along with the patients and their caregivers.
  • Policy leaders are also key stakeholders as they shape the overall environment, fund these often-expensive treatments and can direct investments that focus on enhancing overall processes in the healthcare system.

Share of patients treated with CAR T-cell therapies among drug treated LBCL 2L+ R/R CAR T naïve patients (Evolution between 2022 and 2023)

  • The overall share varies across countries. France had the highest share of patients receiving CAR T in 2023 with 30% and Italy the lowest (11%).
  • Several factors can drive these differences in CAR T share such as the number of treatment centers, the processes for referrals and treatment initiation/ administration, and reimbursement dynamics.

Share of referring providers by level of information received about CAR T-cell therapy, Q2 2024

  • Referring physicians in France, Australia, and Canada note a higher level of knowledge regarding CAR T-cell therapies compared to other countries in scope
  • However, additional information and education programs may be beneficial in all countries with a substantial proportion of referring physicians noting the need for more information

Time between referral and commencement of CAR T treatment, Q2 2024

  • The time between referral and commencement of CAR T treatment for DLBCL varies substantially across countries. Treating physicians in UK and Australia noted the highest proportion of times that were three months or greater
  • Across all countries, there were a large proportion of cases that took two months. These delays after referral can be driven by capacity constraints and operational issues which need to be addressed.

Share of referred patients receiving CAR T treatment, Q2 2024

  • An assessment of the share of referred patients receiving CAR T-cell treatment across countries for DLBCL in Q2 2024 highlights a higher proportion of patients being treated in Italy and Spain compared to other countries. This suggests that other countries may be facing additional challenges postreferral.
  • It should be noted that while Italy has a high proportion of referred patients being treated, it has the lowest share of overall LBCL 2L+ patients receiving CAR T, highlighting that not all patients who may be eligible are referred and the referral process has been noted as a major barrier in Italy

Related solutions

Commercialization

Take advantage of the latest tools, techniques, and deep healthcare expertise to create scalable resources, precision insights, and actionable ideas.

Contact Us